CA
NZ
UK
AU
IND
US
Craneware’s shares fell sharply today as investors reassessed the outlook for revenue cycle management, a segment dealing with tighter payer reimbursements and escalating operational costs. The decline mirrors broader weakness among healthcare technology firms, where billing accuracy and compliance risks have intensified amid regulatory …
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 0.13% in pre-market trading after the company submitted an S-3 registration filing with the SEC on July 17, 2026, facilitating the potential resale of 128,189 common shares by specific stockholders.
Advanced Biomed (NASDAQ: ADVB) shares rose 32% in pre-market trading after the company disclosed via an SEC filing that it has terminated its June 2025 stock purchase agreement with Helena Global Investment Opportunities I.
BioVie Inc. (NASDAQ: BIVI) shares fell 22% in pre-market trading after the company submitted a registration statement to the SEC on July 17, 2026, for a proposed sale of Class A common stock and warrants, with specific pricing and volume details yet to be …
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares were flat in pre-market trading after the company entered into a confidential separation agreement with Chief Medical Officer Dr. James J. Ferguson III following his voluntary resignation notice submitted on July 7, 2026.
Immunome, Inc. (NASDAQ: IMNM) shares were flat in pre-market trading after the company said the initial participant has received a dose in the Phase 1 first-in-human clinical trial evaluating IM-3050, a novel radioligand therapy.
Glucotrack, Inc. (NASDAQ: GCTK) shares fell 12% in pre-market trading after the company finalized a $4.45 million senior secured convertible bridge loan, closed in tandem with a stock-for-stock merger with Lōkahi Therapeutics.
Incyte Corporation (NASDAQ: INCY) is scheduled to present two separate Phase 3 oncology readouts at the ESMO 2026 congress, covering candidates in pancreatic cancer and ovarian cancer.
Kalaris Therapeutics (NASDAQ: KLRS) presented Phase 1a data at the ASRS meeting on July 17, 2026, showing significant gains in visual acuity and retinal thickness for its neovascular age-related macular degeneration candidate, TH103.
Veradermics Incorporated (NASDAQ: MANE) shares closed up 5.19% at $111.32 after the company shared Phase 2/3 data for its male pattern hair loss candidate VDPHL01 at the AAD Innovation Academy on July 17, 2026.
Please wait processing your request...